The role of bile acids in the neoplastic progression of Barrett's esophagus - A short representative overview

Zeitschrift fur Gastroenterologie

Volumn 50, Issue 9, 2012, Pages 1028-1034

  Jurgens S ^a   Meyer, F ^a   Spechler, S J ^b   Souza, R ^b  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

Barrett's esophagus; bile acids; deoxycholic acid (DCA); urodeoxycholic acid (UDCA)

Indexed keywords

BETA GALACTOSIDASE; BILE ACID; DEOXYCHOLIC ACID; DNA; PROTON PUMP INHIBITOR; URSODEOXYCHOLIC ACID;

APOPTOSIS; BARRETT ESOPHAGUS; CANCER GROWTH; CANCER INCIDENCE; CANCER PATIENT; CELL SURVIVAL; CYTOTOXICITY; DISEASE ASSOCIATION; DNA DAMAGE; DRUG EFFICACY; ESOPHAGEAL ADENOCARCINOMA; GASTROESOPHAGEAL REFLUX; HUMAN; HYDROPHOBICITY; INTRAHEPATIC CHOLESTASIS; MOLECULAR BIOLOGY; NONHUMAN; OVERALL SURVIVAL; PATHOPHYSIOLOGY; REVIEW; STOMACH ACID;

BARRETT ESOPHAGUS; BILE ACIDS AND SALTS; ESOPHAGEAL NEOPLASMS; HUMANS; MODELS, BIOLOGICAL; PARANEOPLASTIC SYNDROMES; PRECANCEROUS CONDITIONS;

EID: 84865828003     PISSN: 00442771     EISSN: 14397803     Source Type: Journal    
DOI: 10.1055/s-0032-1312922     Document Type: Review

References (67)

1. Quaroni L, Zhao R, Casson AG. Shining light on Barrett's esophagus. Expert Rev Gastroenterol Hepatol: 2009; 3 577 580
2. El Rifai W, Powell SM. Molecular biology of gastric cancer. Semin Radiat Oncol: 2002; 12 128 140
3. Zhang HY, Spechler SJ, Souza RF. Esophageal adenocarcinoma arising in Barrett esophagus. Cancer Lett: 2009; 275 170 177
4. Pascu O, Lencu M. Barrett's Esophagus. Romanian J Gastroenterol: 2004; 13 219 222
5. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst: 2005; 97 142 146
6. Spechler SJ, Sharma P, Souza RF et al. American Gastroenterological Association Medical Position Statement of the Management of Barrett's Esophagus. Gastroenterology: 2011; 140 1084 1091
7. Souza RF, Spechler SJ. Concepts in the prevention of adenocarcinoma of the distal esophagus and proximal stomach. CA Cancer J Clin: 2005; 55 334 351
8. Eloubeidi MA, Mason AC, Desmond RA et al. Temporal trends (1973-1997) in survival of patients with esophageal adenocarcinoma in the United States: a glimmer of hope? Am J Gastroenterol: 2003; 98 1627 1633
9. Hvid-Jensen F, Pedersen L, Drewes AM et al. Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med: 2011; 365 1375 1383
10. Wang X, Ouyang H, Yamamoto Y et al. Residual embryonic cells as precursors of a Barrett's-like metaplasia. Cell: 2011; 145 1023 1035
11. Tosh D, Slack JM. How cells change their phenotype. Nat Rev Mol Cell Biol: 2002; 3 187 194
12. Souza RF, Krishnan K, Spechler SJ. Acid, bile, and CDX: the ABCs of making Barrett's metaplasia. Am J Physiol Gastrointest Liver Physiol: 2008; 295 G211 G218
13. Hutchinson L, Stenstrom B, Chen D et al. Human Barrett's adenocarcinoma of the esophagus, associated myofibroblasts, and endothelium can arise from bone marrow-derived cells after allogeneic stem cell transplant. Stem Cells Dev: 2011; 20 11 17
14. Fitzgerald RC, Lascar R, Triadafilopoulos G. Review article: Barrett's oesophagus, dysplasia and pharmacologic acid suppression. Aliment Pharmacol Ther: 2001; 15 269 276
15. Tobey NA, Hosseini SS, Caymaz-Bor C et al. The role of pepsin in acid injury to esophageal epithelium. Am J Gastroenterol: 2001; 96 3062 3070
16. Ismail-Beigi F, Horton PF, Pope CE. Histological consequences of gastroesophageal reflux in man. Gastroenterology: 1970; 58 163 174
17. Orlando RC. Pathophysiology of gastroesophageal reflux disease. J Clin Gastroenterol: 2008; 42 584 588
18. Souza RF, Huo X, Mittal V et al. Gastroesophageal reflux might cause esophagitis through a cytokine-mediated mechanism rather than caustic acid injury. Gastroenterology: 2009; 137 1776 1784
19. Rieder F, Biancani P, Harnett K et al. Inflammatory mediators in gastroesophageal reflux disease: impact on esophageal motility, fibrosis, and carcinogenesis. Am J Physiol Gastrointest Liver Physiol: 2010; 298 G571 G581
20. Dobbagh K, Takeyama K, Lee H et al. IL-4 induces mucin gene expression and goblet cell metaplasia in vitro and in vivo. J Immunol: 1999; 162 6233 6237
21. Yoshida N. Inflammation and Oxidative Stress in Gastroesophageal Reflux Disease. J Clin Biochem Nutr: 2007; 40 13 23
22. Salminen JT, Tuominen JA, Rämö OJ et al. Oesophageal acid exposure: higher in Barrett's oesophagus than in reflux oesophagitis. Ann Med: 1999; 31 46 50
23. Katz PO. The role of non-acid reflux in gastro-oesophageal reflux disease. Aliment Pharmacol Ther: 2000; 14 1539 1551
24. Perez MJ, Briz O. Bile-acid-induced cell injury and protection. World J Gastroenterol: 2009; 15 1677 1689
25. Frazzoni M, Conigliaro R, Melotti G. Weakly acidic refluxes have a major role in the pathogenesis of proton pump inhibitor-resistant reflux oesophagitis. Aliment Pharmacol Ther: 2011; 33 601 606
26. Nehra D, Howell P, Williams CP et al. Toxic bile acids in gastro-oesophageal reflux disease: influence of gastric acidity. Gut: 1999; 44 598 602
27. Mahmoud NN, Dannenberg AJ, Bilinski RT et al. Administration of an unconjugated bile acid increases duodenal tumors in a murine model of familial adenomatous polyposis. Carcinogenesis: 1999; 20 299 303
28. Kauer WK, Peters JH, DeMeester TR et al. Mixed reflux of gastric and duodenal juices is more harmful to the esophagus than gastric juice alone. The need for surgical therapy re-emphasized. Ann Surg: 1995; 222 525 531
29. Billington D, Evans CE, Godfrey PP et al. Effects of bile salts on the plasma membranes of isolated rat hepatocytes. Biochem J: 1980; 188 321 327
30. Gores GJ, Miyoshi H, Botla R et al. Induction of the mitochondrial permeability transition as a mechanism of liver injury during cholestasis: a role for mitochondrial proteases. Biochem Biophys Acta: 1998; 1366 167 175
31. Vaezi MF, Richter JE. Duodenogastro-oesophageal reflux. Baillieres Best Pract Res Clin Gastroenterol: 2000; 14 719 729
32. Chen X, Yang CS. Esophageal adenocarcinoma: a review and perspectives on the mechanism of carcinogenesis and chemoprevention. Carcinogenesis: 2001; 22 1119 1129
33. Crowley-Weber CL, Payne CM, Gleason-Guzman M et al. Development and molecular characterisation of HCT-116 cell lines resistant to the tumor promoter and multiple stress-inducer, deoxycholate. Carcinogenesis: 2008; 23 2063 2080
34. Hellerbrand C, Hoeger S, Muelbauer M et al. Bile acids induce proinflammatory cytokine expression in activated hepatic stellate cells via NFKB activation. Hepatology: 2000; 32 156
35. Burnat G, Majka J, Konturek PC. Bile acids are multifunctional modulators of the Barrett's carcinogenesis. J Physiol Pharmacol: 2010; 61 185 192
36. Scates DK, Venitt S, Phillips RK et al. High pH reduces DNA damage caused by bile from patients with familial adenomatous polyposis - antacids may attenuate duodenal polyposis. Gut: 1995; 36 918 921
37. Booth LA, Gilmore IT, Bilton RF. Secondary bile acid induced DNA damage in HT29 cells: are free radicals involved? Free Radic Res: 1997; 26 135 144
38. Hatada EN, Nieters A, Wulczyn FG et al. The ankyrin repeat domains of the NF-kappa B precursor p105 and the protooncogene bcl-3 act as specific inhibitors of NF-kappa B DNA binding. Proc Natl Acad Sci USA: 1992; 89 2489 2493
39. Ghosh S, Karin M. Missing pieces in the NF-kappaB puzzle. Cell: 2002; 109 81 96
40. Ravi R, Bedi A. NF-kappaB in cancer - a friend turned foe. Drug Resist Updat: 2004; 7 53 67
41. Van Waes C. Nuclear factor-κB in development, prevention, and therapy of Cancer. Clin Cancer Res: 2007; 13 1076 1082
42. Karin M, Cao Y, Greten FR et al. NF-κB in cancer: from innocent bystander to major culprit. Nature Rev Cancer: 2002; 2 301 310
43. Dvorakova K, Payne CM, Ramsey L et al. Apoptosis resistance in Barrett's esophagus: ex vivo bioassay of live stressed tissues. Am J Gastroenterol: 2005; 100 424 431
44. Katada N, Hinder RA, Smyrk TC et al. Apoptosis is inhibited early in the dysplasia-carcinoma sequence of Barrett esophagus. Arch Surg: 1997; 132 728 733
45. Van de Meeberg PC, van Erpecum KJ, van Berge-Henegouwen GP. Therapy with ursodeoxycholic acid in cholestatic liver disease. Scand J Gastroenterol: 1993; 200 15 20
46. Stiehl A. Treatment of cholestatic liver diseases; the role of ursodeoxycholic acid. Z Gastroenterol: 1992; 30 743 747
47. Rodrigues CM, Fan G, Wong PY et al. Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production. Mol Med: 1998; 4 165 178
48. Croog VJ, Ullman TA, Itzkowitz SH. Chemoprevention of colorectal cancer in ulcerative colitis. Int J Colorectal Dis: 2003; 18 392 400
49. Huo X, Juergens S, Zhang X et al. Deoxycholic acid causes DNA damage while inducing apoptotic resistance through NF-κB activation in benign Barrett's epithelial cells. Am J Physiol Gastrointest Liver Physiol: 2011; 301 G278 G286
50. Hormi-Carver K, Zhang X, Zhang HY et al. Unlike esophageal squamous cells, Barrett's epithelial cells resist apoptosis by activating the nuclear factor-kappaB pathway. Cancer Res: 2009; 69 672 677
51. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell: 2000; 100 57 70
52. Jenkins GJ, Cronin J, Alhamdani A et al. The bile acid deoxycholic acid has a non-linear dose response for DNA damage and possibly NF-kappaB activation in oesophageal cells, with a mechanism of action involving ROS. Mutagenesis: 2008; 23 3399 3405
53. Jenkins GJ, Harries K, Doak SH et al. The bile acid deoxycholic acid (DCA) at neutral pH activates NF-kappaB and induces IL-8 expression in oesophageal cells in vitro. Carcinogenesis: 2004; 25 317 323
54. Armstrong D, Rytina ER, Murphy GM et al. Gastric mucosal toxicity of duodenal juice constituents in the rat. Acute studies using ex vivo rat gastric chamber model. Dig Dis Sci: 1994; 39 327 339
55. Lee DK, Park SY, Baik SK et al. Deoxycholic acid-induced signal transduction in HT-29 cells: role of NF-kappa B and interleukin-8. Korean J Gastroenterol: 2004; 43 176 185
56. Amaral JD, Viana RJ, Ramalho RM et al. Bile acids: regulation of apoptosis by ursodeoxycholic acid. J Lipid Res: 2009; 50 1721 1734
57. Schoemaker MH, Gommans WM, Conde de la Rosa L et al. Resistance of rat hepatocytes against bile acid-induced apoptosis in cholestatic liver injury is due to nuclear factor-kappa B activation. J Hepatol: 2003; 39 153 161
58. Beuers U, Boyer JL, Paumgartner G. Ursodeoxycholic acid in cholestasis: potential mechanisms of action and therapeutic applications. Hepatology: 1998; 28 1449 1453
59. Rodrigues CM, Fan G, Ma X et al. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest: 1998; 101 2790 2799
60. Tung BY, Emond MJ, Haggitt RC et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med: 2001; 134 89 95
61. Serfaty L, De Leusse A, Rosmorduc O et al. Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: an observational study. Hepatology: 2003; 38 203 209
62. Im E, Martinez JD. Ursodeoxycholic acid (UDCA) can inhibit deoxycholic acid (DCA)-induced apoptosis via modulation of EGFR/Raf-1/ERK signaling in human colon cancer cells. J Nutr: 2004; 134 483 486
63. Rizvi S, Demars CJ, Comba A et al. Combinatorial chemoprevention reveals a novel smoothened-independent role of GLI1 in esophageal carcinogenesis. Cancer Res: 2010; 70 6787 6796
64. Vaezi MF, Richter JE. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology: 1996; 111 1192 1199
65. Raj A, Jankowski J. Acid suppression and chemoprevention in Barrett's oesophagus. Dig Dis: 2004; 22 171 180
66. Abrams JA. Chemoprevention of esophageal adenocarcinoma. Therap Adv Gastroenterol: 2008; 1 7 18
67. Mehta SP, Body AP, Cook I et al. Effect of n-3 polyunsaturated fatty acids on Barrett's epithelium in human lower esophagus. Am J Clin Nutr: 2008; 87 949 956